Remove clinical substance-use-disorder
article thumbnail

Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders

Pharmafile

Summary: • TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero Bio • Phase 1 study in healthy volunteers expected to begin in Q1 2023 with support from a US$5.3M read more.

FDA 40
article thumbnail

Virtual SUD clinic Pelago clinches $58M to expand offerings for payers, employers

Fierce Healthcare

Pelago, a virtual substance use disorder (SUD) clinic working with payers and employers, has clinched $58 million in a series C round. Pelago offers integrated SUD management for employers and payers, with specialized treatment for tobacco, alcohol and opioid use disorders.

68
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Large network of clinics offering ketamine for depression shuts down

STAT

One of the largest operators of ketamine clinics in the country abruptly closed its facilities this week, leaving patients in the dark and out of treatment for depression and other chronic conditions. And there is a push by some to expand its use to treat other conditions , such as substance use disorders.

103
103
article thumbnail

Psychedelic medicines: are they gaining traction in Europe?

European Pharmaceutical Review

Psychedelics are a class of psychoactive substances that produce temporary changes in perception, mood and cognitive processes. 2 LSD is widely known as the archetypal psychedelic from the 1960s, though there are also many other substances described as psychedelics. As a result, medical use ceased and research stopped across the globe.

article thumbnail

STAT+: Telehealth companies that prescribed controlled substances during the pandemic brace for business to change

STAT

Health tech companies that have taken advantage of the possibility to prescribe controlled substances online during the pandemic may soon find their businesses — and their ability to care for patients — in jeopardy.    Continue to STAT+ to read the full story…

article thumbnail

Digital health tech: a solution to substance use disorders?

Pharmaceutical Technology

Healthcare providers are under pressure to address the growing issue of substance use disorders. Substance use disorders leave people with long-term negative mental and physical health implications and can lead to death.

FDA 52
article thumbnail

What are the most common depression medications?

The Checkup by Singlecare

Whether you need support during a short-term period of grief and loss or you live with long-term depression , your healthcare provider may recommend the use of an antidepressant. Some are also approved for anxiety disorders or fibromyalgia. chief medical officer and co-founder of Toolbox Genomics.